BBR Partners LLC Invests $110,000 in Viemed Healthcare, Inc. (NASDAQ:VMD)

BBR Partners LLC acquired a new stake in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 15,000 shares of the company’s stock, valued at approximately $110,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Viemed Healthcare by 53.0% during the first quarter. Vanguard Group Inc. now owns 1,781,914 shares of the company’s stock valued at $16,803,000 after purchasing an additional 617,009 shares in the last quarter. Apis Capital Advisors LLC grew its holdings in Viemed Healthcare by 193.0% during the 2nd quarter. Apis Capital Advisors LLC now owns 234,400 shares of the company’s stock worth $1,535,000 after acquiring an additional 154,400 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Viemed Healthcare during the 1st quarter worth approximately $97,000. Oppenheimer Asset Management Inc. raised its stake in shares of Viemed Healthcare by 5.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 30,222 shares of the company’s stock valued at $222,000 after acquiring an additional 1,601 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY lifted its holdings in shares of Viemed Healthcare by 25.0% during the second quarter. Paradigm Capital Management Inc. NY now owns 400,000 shares of the company’s stock worth $2,620,000 after purchasing an additional 80,000 shares during the period. Institutional investors own 74.24% of the company’s stock.

Viemed Healthcare Stock Performance

Shares of Viemed Healthcare stock opened at $8.56 on Friday. The stock has a market cap of $333.33 million, a price-to-earnings ratio of 31.70 and a beta of 1.43. Viemed Healthcare, Inc. has a twelve month low of $6.21 and a twelve month high of $10.44. The company’s fifty day moving average is $8.56 and its 200 day moving average is $7.59. The company has a quick ratio of 1.19, a current ratio of 1.31 and a debt-to-equity ratio of 0.03.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. The firm had revenue of $58.00 million for the quarter. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%.

Insiders Place Their Bets

In related news, Director Randy E. Dobbs sold 36,261 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $9.28, for a total transaction of $336,502.08. Following the sale, the director now owns 107,706 shares in the company, valued at $999,511.68. This represents a 25.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nitin Kaushal sold 5,995 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $8.58, for a total value of $51,437.10. Following the sale, the director now directly owns 126,843 shares of the company’s stock, valued at $1,088,312.94. This represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,256 shares of company stock worth $674,739. 20.00% of the stock is currently owned by insiders.

About Viemed Healthcare

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.